794 related articles for article (PubMed ID: 14759561)
1. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
2. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
5. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
[TBL] [Abstract][Full Text] [Related]
7. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
8. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
[TBL] [Abstract][Full Text] [Related]
10. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
12. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
[TBL] [Abstract][Full Text] [Related]
13. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
14. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
Jeibmann A; Zahedi S; Simoni M; Nieschlag E; Byrne MM
Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
[TBL] [Abstract][Full Text] [Related]
16. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
18. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
[TBL] [Abstract][Full Text] [Related]
19. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
20. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
